Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endocrinology | 37 | 2023 | 124 | 12.890 |
Why?
|
| Diabetes Mellitus | 37 | 2025 | 889 | 8.670 |
Why?
|
| Diabetes Mellitus, Type 1 | 25 | 2026 | 895 | 3.730 |
Why?
|
| Reference Standards | 35 | 2023 | 231 | 3.500 |
Why?
|
| Standard of Care | 35 | 2023 | 133 | 3.460 |
Why?
|
| Societies, Medical | 36 | 2023 | 798 | 2.740 |
Why?
|
| Transition to Adult Care | 9 | 2026 | 131 | 2.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 8 | 2023 | 1459 | 1.450 |
Why?
|
| Diabetic Ketoacidosis | 3 | 2025 | 170 | 1.060 |
Why?
|
| Retinal Diseases | 2 | 2023 | 142 | 0.780 |
Why?
|
| Insulin | 5 | 2022 | 1149 | 0.670 |
Why?
|
| Humans | 66 | 2026 | 131163 | 0.640 |
Why?
|
| Blood Glucose | 7 | 2023 | 1117 | 0.630 |
Why?
|
| Hypoglycemic Agents | 8 | 2023 | 480 | 0.590 |
Why?
|
| Prescription Drugs | 1 | 2020 | 54 | 0.580 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2018 | 13 | 0.560 |
Why?
|
| Hyperglycemia | 1 | 2020 | 234 | 0.530 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 265 | 0.500 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2023 | 853 | 0.480 |
Why?
|
| Adolescent | 24 | 2026 | 20987 | 0.450 |
Why?
|
| Dyslipidemias | 1 | 2018 | 256 | 0.450 |
Why?
|
| Blood Glucose Self-Monitoring | 4 | 2023 | 129 | 0.400 |
Why?
|
| Adolescent Development | 1 | 2013 | 29 | 0.390 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 2121 | 0.360 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 744 | 0.350 |
Why?
|
| Attitude of Health Personnel | 2 | 2024 | 707 | 0.330 |
Why?
|
| Young Adult | 15 | 2026 | 10103 | 0.320 |
Why?
|
| Comorbidity | 4 | 2023 | 1595 | 0.310 |
Why?
|
| Physicians | 1 | 2015 | 635 | 0.280 |
Why?
|
| Child | 15 | 2025 | 26341 | 0.270 |
Why?
|
| Social Support | 2 | 2026 | 370 | 0.270 |
Why?
|
| Clinical Competence | 1 | 2015 | 1050 | 0.270 |
Why?
|
| Self-Management | 2 | 2026 | 120 | 0.260 |
Why?
|
| Peer Group | 2 | 2026 | 128 | 0.250 |
Why?
|
| Mentors | 2 | 2026 | 170 | 0.240 |
Why?
|
| Southwestern United States | 1 | 2025 | 46 | 0.220 |
Why?
|
| Protective Factors | 1 | 2025 | 91 | 0.220 |
Why?
|
| Insulin Infusion Systems | 3 | 2020 | 67 | 0.210 |
Why?
|
| Affect | 1 | 2025 | 159 | 0.210 |
Why?
|
| Female | 20 | 2026 | 70963 | 0.200 |
Why?
|
| Hypertriglyceridemia | 1 | 2025 | 117 | 0.200 |
Why?
|
| Adult | 16 | 2026 | 31282 | 0.200 |
Why?
|
| Liraglutide | 1 | 2022 | 15 | 0.190 |
Why?
|
| Sleep Wake Disorders | 1 | 2025 | 204 | 0.180 |
Why?
|
| Hospitals | 2 | 2023 | 435 | 0.180 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2022 | 77 | 0.180 |
Why?
|
| Quality Improvement | 3 | 2023 | 722 | 0.180 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2023 | 130 | 0.170 |
Why?
|
| Cross-Sectional Studies | 6 | 2021 | 3829 | 0.170 |
Why?
|
| Recurrence | 1 | 2025 | 1489 | 0.170 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2025 | 919 | 0.160 |
Why?
|
| Male | 15 | 2026 | 64957 | 0.160 |
Why?
|
| Stress, Psychological | 1 | 2025 | 536 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2025 | 512 | 0.150 |
Why?
|
| Vaccination | 1 | 2025 | 1060 | 0.150 |
Why?
|
| Health Personnel | 1 | 2024 | 541 | 0.150 |
Why?
|
| Diabetes Complications | 1 | 2020 | 197 | 0.150 |
Why?
|
| Autoantibodies | 1 | 2022 | 451 | 0.150 |
Why?
|
| Passeriformes | 1 | 2008 | 1 | 0.140 |
Why?
|
| Spatial Behavior | 1 | 2008 | 13 | 0.140 |
Why?
|
| Reproductive Health | 1 | 2018 | 48 | 0.140 |
Why?
|
| Exploratory Behavior | 1 | 2008 | 52 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2021 | 282 | 0.130 |
Why?
|
| Child, Preschool | 5 | 2025 | 15110 | 0.130 |
Why?
|
| Self Care | 3 | 2026 | 231 | 0.130 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 327 | 0.130 |
Why?
|
| Pregnancy | 4 | 2023 | 7512 | 0.120 |
Why?
|
| Severity of Illness Index | 1 | 2025 | 3061 | 0.120 |
Why?
|
| Health Education | 1 | 2018 | 228 | 0.120 |
Why?
|
| Depression | 1 | 2025 | 1320 | 0.120 |
Why?
|
| Behavior, Animal | 1 | 2008 | 480 | 0.110 |
Why?
|
| Risk Factors | 3 | 2025 | 11074 | 0.110 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1173 | 0.110 |
Why?
|
| Adrenal Hyperplasia, Congenital | 1 | 2014 | 31 | 0.110 |
Why?
|
| Infant, Newborn | 2 | 2025 | 8635 | 0.110 |
Why?
|
| Pediatrics | 2 | 2014 | 1252 | 0.100 |
Why?
|
| Physicians, Primary Care | 1 | 2015 | 100 | 0.100 |
Why?
|
| Psychology, Adolescent | 1 | 2013 | 34 | 0.100 |
Why?
|
| Obesity | 2 | 2023 | 2426 | 0.100 |
Why?
|
| Puberty | 1 | 2013 | 94 | 0.100 |
Why?
|
| Patient Care Planning | 1 | 2013 | 124 | 0.090 |
Why?
|
| Hospitalization | 1 | 2021 | 1950 | 0.090 |
Why?
|
| Hypertension | 1 | 2020 | 1356 | 0.090 |
Why?
|
| Infant | 2 | 2025 | 13352 | 0.090 |
Why?
|
| Adolescent Behavior | 1 | 2013 | 166 | 0.090 |
Why?
|
| United States | 4 | 2021 | 12072 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 464 | 0.080 |
Why?
|
| Precision Medicine | 1 | 2013 | 388 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 1295 | 0.070 |
Why?
|
| Primary Health Care | 1 | 2013 | 775 | 0.070 |
Why?
|
| Retrospective Studies | 1 | 2025 | 17753 | 0.060 |
Why?
|
| Aged | 2 | 2023 | 21025 | 0.060 |
Why?
|
| Learning | 2 | 2020 | 356 | 0.060 |
Why?
|
| Registries | 2 | 2021 | 1634 | 0.050 |
Why?
|
| Pancreatitis | 1 | 2025 | 139 | 0.050 |
Why?
|
| Age Factors | 2 | 2021 | 2825 | 0.050 |
Why?
|
| Benchmarking | 1 | 2023 | 137 | 0.050 |
Why?
|
| Quality of Life | 2 | 2024 | 2082 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2018 | 12936 | 0.040 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2021 | 18 | 0.040 |
Why?
|
| Off-Label Use | 1 | 2021 | 29 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 4066 | 0.040 |
Why?
|
| Parity | 1 | 2020 | 77 | 0.040 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2020 | 33 | 0.040 |
Why?
|
| Sodium | 1 | 2021 | 280 | 0.040 |
Why?
|
| Biomarkers | 2 | 2021 | 3385 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 512 | 0.040 |
Why?
|
| Health Behavior | 1 | 2023 | 387 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2023 | 562 | 0.040 |
Why?
|
| Cholesterol, HDL | 1 | 2020 | 383 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2021 | 825 | 0.040 |
Why?
|
| Age of Onset | 1 | 2020 | 592 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 1267 | 0.030 |
Why?
|
| Orientation | 1 | 2008 | 35 | 0.030 |
Why?
|
| Space Perception | 1 | 2008 | 50 | 0.030 |
Why?
|
| Cues | 1 | 2008 | 80 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2020 | 320 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 915 | 0.030 |
Why?
|
| Triglycerides | 1 | 2020 | 602 | 0.030 |
Why?
|
| Glucose | 1 | 2021 | 853 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2020 | 604 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2023 | 844 | 0.030 |
Why?
|
| Counseling | 1 | 2016 | 238 | 0.030 |
Why?
|
| Curriculum | 1 | 2020 | 798 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 2200 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2023 | 5196 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 1445 | 0.030 |
Why?
|
| Prevalence | 1 | 2021 | 2701 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 2304 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2021 | 3711 | 0.020 |
Why?
|
| Prognosis | 1 | 2021 | 4886 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 645 | 0.020 |
Why?
|
| Texas | 1 | 2018 | 3686 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 6196 | 0.020 |
Why?
|
| Animals | 1 | 2008 | 33912 | 0.010 |
Why?
|